Functional Capacity Assessment for Motor Neurone Disease

Functional Capacity Assessment for Motor Neurone Disease, Sina OT

MND referrals are treated as high priority

Motor neurone disease progresses rapidly and relentlessly. The window of opportunity for assessment, planning and equipment prescription narrows from the moment of diagnosis.

Communication technology must be trialled and prescribed while the person still has sufficient motor function to learn and use it. Waiting until speech is severely impaired may mean the person can no longer trial or operate the technology effectively.

Assessment and NDIS planning for MND should begin as soon as possible after diagnosis — not when needs become urgent.

Motor neurone disease (MND) is a group of progressive neurodegenerative conditions in which the nerve cells controlling voluntary muscle movement gradually fail and die. The result is progressive muscle weakness, wasting and paralysis that ultimately affects the ability to move, speak, swallow and breathe. MND is universally fatal. Approximately 2,750 Australians are living with MND at any one time. Survival from onset of symptoms is typically two to five years, though approximately ten per cent of people with MND live for ten or more years. MND most commonly affects people in their mid-to-late fifties and early sixties, though it can occur at any adult age.

MND is also known as Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease. There is currently no cure. Two medications are approved in Australia that can modestly slow disease progression, but MND remains rapidly and relentlessly progressive in most cases. The clinical focus for people with MND is on maintaining quality of life and independence for as long as possible, ensuring that the right supports and equipment are in place before they are needed rather than after and ensuring that the person’s values and preferences guide all planning decisions.

Types of MND

MND encompasses several related but clinically distinct conditions that differ in which motor neurons are primarily affected and the pattern of symptom onset and progression.

Type

Clinical characteristics

Amyotrophic Lateral Sclerosis (ALS)

The most common form, affecting approximately 90 per cent of people with MND. Both upper motor neurons (in the brain) and lower motor neurons (in the spinal cord) are affected. Produces a combination of spasticity and muscle weakness. Typically begins with focal limb weakness or bulbar symptoms and progresses to involve all voluntary muscle groups. Average survival 2 to 5 years.

Progressive Bulbar Palsy (PBP)

Affects the bulbar motor neurons that control speech and swallowing first. Presents initially with difficulty speaking and swallowing. Communication and nutrition become critical early concerns. Typically progresses to involve the limbs and respiratory system. Often has faster progression than limb-onset ALS.

Progressive Muscular Atrophy (PMA)

Affects primarily lower motor neurons, producing muscle wasting and weakness without the spasticity seen in upper motor neuron disease. Slower progression than ALS in many cases.

Primary Lateral Sclerosis (PLS)

Affects primarily upper motor neurons, producing spasticity and weakness with slower progression than ALS. Some people with PLS have a significantly longer survival than typical ALS.

How MND progresses: onset patterns and their implications

MND can begin in different parts of the body and progress in different patterns. Understanding the onset pattern is clinically relevant because it determines which functional domains will deteriorate first and which supports must be prioritised in NDIS planning.

  • Limb onset: weakness beginning in the hands or feet, progressing to the arms and legs. Initially affects fine motor tasks, grip strength and walking. Progresses to require increasing assistance with all physical tasks including self-care and mobility. Power wheelchair prescription should be initiated as early as possible in the progression to allow adequate trialling and training while the person still has sufficient upper limb and cognitive function to operate the chair.
  • Bulbar onset: weakness beginning in the muscles of the tongue, throat and mouth, affecting speech and swallowing before the limbs are significantly involved. Communication technology assessment is the most urgent priority in bulbar onset MND and must begin immediately. Dysphagia management and dietary modification are also critical early concerns.
  • Respiratory onset: the least common onset pattern, where respiratory muscle weakness presents before significant limb or bulbar involvement. Breathing support including non-invasive ventilation is the most urgent clinical priority.

Why timing is the defining clinical urgency in MND

In every other condition addressed in this series of articles, assessment and planning are important but the person generally has time. In MND, time is the defining clinical constraint. Every week of delay in assessment, NDIS application and equipment prescription is a week of declining function during which the window for effective planning and trialling narrows.

Communication technology: the most time-critical prescription

The ability to communicate — to express preferences, make decisions, maintain relationships and participate in planning one’s own care — is among the things most people with MND identify as most important to their quality of life. As verbal speech declines in MND, augmentative and alternative communication (AAC) technology becomes the primary means of communication. AAC technology for MND ranges from simple low-tech communication boards through to sophisticated high-tech eye gaze systems that allow communication using only eye movement.

The critical clinical issue is that AAC technology must be trialled, prescribed and funded before speech deteriorates to the point where the person cannot trial the technology or before motor function deteriorates to the point where they cannot learn to operate it. A person who receives eye gaze technology only after they have lost the ability to speak and whose upper limb movement is already severely restricted will have had no opportunity to trial and learn the system while they still had sufficient function to practise. The result is that a device which could have provided ongoing communication is either not usable or is used only minimally.

The speech pathologist leads the AAC assessment, prescription and funding process. The Occupational Therapist contributes to the assessment by evaluating the motor and positioning requirements for device access including mounting systems, positioning equipment and the integration of the AAC device into the power wheelchair where relevant.

Power wheelchair: the second most time-critical prescription

For people with MND whose disease course will affect walking, a power wheelchair must be prescribed and funded while the person still has sufficient hand and arm function to operate the joystick and sufficient cognitive and physical capacity to trial the chair effectively. A power wheelchair prescription for MND is a complex clinical process involving assessment of current and anticipated motor function, the specific drive control system most appropriate for the person’s hand function and its likely trajectory, the seating and positioning system required for postural support and pressure care and the home and community environments in which the chair will be used.

If the power wheelchair is not funded and available until the person can no longer walk, they will have had no opportunity to practise and they will be managing the transition to full wheelchair use at the most distressing and physically demanding time of the disease course without the independent mobility the chair provides. The OT assessment must anticipate the person’s likely motor trajectory and prescribe for where they will be in six to twelve months, not only for where they are today.

How MND affects daily functioning

Upper and lower limb function

Progressive weakness and wasting of the arm and hand muscles affects all fine motor tasks including writing, using cutlery, dressing, personal hygiene and operating technology. Grip strength and pinch strength decline progressively. As the legs weaken, walking becomes unsafe and eventually impossible. Transfers, including moving between sitting and standing and in and out of bed, require increasing assistance. Spasticity in upper motor neuron disease adds stiffness and discomfort to the weakness and wasting.

Speech and communication

Dysarthria — slurred and increasingly unclear speech — develops in the majority of people with MND as the muscles of the mouth, tongue and throat weaken. Voice volume often reduces. In bulbar onset MND, speech deterioration may begin early. The progression from mild dysarthria through severe dysarthria to anarthria — the complete inability to produce intelligible speech — can occur over months. The Functional Capacity Assessment must document speech intelligibility at the time of assessment, the trajectory of deterioration and the urgency of AAC assessment and funding.

Swallowing

Dysphagia affects the majority of people with MND as the disease progresses and involves all stages of swallowing. Food and liquid aspiration — entry into the airway — creates a serious risk of aspiration pneumonia, a major cause of hospitalisation and death in MND. Dysphagia management involves dietary texture and fluid modification, positioning strategies for eating and in advanced disease, consideration of enteral feeding through a percutaneous endoscopic gastrostomy (PEG) tube. The Functional Capacity Assessment must document swallowing status and the support required for safe eating and drinking, in coordination with the speech pathologist.

Respiratory function

Respiratory muscle weakness is the primary cause of death in MND. As the muscles of breathing weaken, the person becomes increasingly unable to maintain adequate ventilation and to clear secretions effectively. Non-invasive ventilation (NIV) via mask provides respiratory support and is associated with improved survival and quality of life. Respiratory function must be monitored regularly by the respiratory team. The Functional Capacity Assessment must document the person’s respiratory status, the level of respiratory support in place and the implications for daily activity capacity.

Personal care and activities of daily living

Personal care requirements increase progressively as MND advances. Initially, adaptations and modified techniques allow greater independence. As the disease progresses, increasing physical assistance is required for all personal care tasks including bathing, dressing, toileting and eating. The level of personal care support required at each stage of the disease must be documented, along with the anticipated trajectory as the disease advances.

Cognitive changes

The majority of people with MND have intact cognition throughout the disease course. However, a proportion — approximately 15 per cent — develop features of frontotemporal dementia (FTD) in association with MND. A further proportion experience milder cognitive changes including executive functioning difficulties and behavioural changes without meeting the criteria for FTD. Where cognitive changes are present, they have direct implications for decision-making capacity, advance care planning and the way in which NDIS planning and communication should be conducted. The Functional Capacity Assessment should note any concerns about cognitive changes and recommend further assessment where indicated.

Advance care planning and values-based care

Advance care planning is a critical component of care for people with MND. This involves the person documenting their values, preferences and wishes regarding their future medical care, including decisions about ventilatory support, enteral feeding and the circumstances under which they would wish treatment to be withdrawn. The ability to participate meaningfully in advance care planning requires that the person has retained sufficient communication capacity to express their wishes. This is another reason why AAC assessment and planning must occur as early as possible in the disease course.

The Functional Capacity Assessment for MND must be conducted in a manner that is responsive to the person’s values and goals. Recommendations for equipment and supports should be framed in terms of how they support the things the person has identified as most important to them — communication, independence, dignity, family participation — rather than simply as clinical recommendations in isolation.

MND and NDIS access

MND is included in NDIS Condition List B. The diagnosis alone does not establish NDIS eligibility — functional evidence of substantially reduced functional capacity is required. For people with MND, the urgency of NDIS access means that the access application and the Functional Capacity Assessment should begin as soon as possible after diagnosis.

The NDIS plan for a person with MND must be designed to meet both current and anticipated future needs. A plan that only funds current supports will be inadequate within months. The OT assessment must document the anticipated trajectory of the condition and provide clinical reasoning for supports and equipment that will be needed as the disease progresses, not only for the present moment.

What a Functional Capacity Assessment covers for MND

  • Assessment of current upper and lower limb function and the specific tasks affected at this stage of the disease
  • Assessment of speech intelligibility and the urgency of AAC assessment and funding
  • Assessment of swallowing and the support and dietary modifications required for safe eating and drinking
  • Assessment of respiratory status and the implications for daily activity capacity and support needs
  • Assessment of current mobility and the anticipatory prescription of power wheelchair and related positioning equipment where clinically indicated
  • Assessment of personal care requirements at the current stage of the disease and anticipated future requirements
  • Assessment of home environment and the modifications and assistive technology required currently and in anticipation of progressive disease
  • Documentation of the anticipated functional trajectory and clinical reasoning for supports and equipment that will be required as the disease progresses
  • Prospective recommendations developed in the context of the person’s stated values and goals
  • Recommendations for carer training and support given the progressive physical demands of MND care

The 2026 NDIS context

The Securing the NDIS for Future Generations Bill 2026, introduced to Parliament on 14 May 2026, strengthens the requirement that NDIS supports must have a direct causal connection to the eligible impairment. For people with MND, the progressive nature of the condition means the Functional Capacity Assessment must document not only current impairment but also the anticipated trajectory and the prospective support requirements that will arise as the disease advances. Plans that do not account for progression will be inadequate and will require review at a time when the person may have significantly less capacity to participate in the review process.

Who can refer?

Referrals are accepted from participants and families, support coordinators, neurologists, MND nursing services, palliative care teams and GPs. Sina OT treats MND referrals as high priority. Contact Sina OT as soon as possible following diagnosis. Assessments are available across Adelaide, Melbourne and Sydney. All assessments are completed in person in the participant’s home.

Disclaimer

The information in this article is provided for general informational purposes only. NDIS rules, legislation, policy and clinical frameworks are subject to change. Sina OT does not accept responsibility for decisions made in reliance on information contained in this article. Participants, families, support coordinators and other professionals should always refer directly to the NDIS website at ndis.gov.au and consult with qualified professionals regarding their individual circumstances.

Refer to Sina OT — MND Referrals Treated as High Priority

Given the rapidly progressive nature of MND, Sina OT treats all MND referrals as high priority. Contact us as soon as possible following diagnosis.

Sina OT is an independent Occupational Therapy practice providing Functional Capacity Assessments across Adelaide, Melbourne and Sydney. Sina OT has completed Functional Capacity Assessments for individuals with motor neurone disease. All assessments are completed in person in the participant’s home by a registered Occupational Therapist.

Services are available in English and Farsi (Persian).

Related Insight Articles

NDIS Funding Changes 2026: The High Support Needs Safeguard Pathway Explained

NDIS Funding Changes 2026: The High Support Needs Safeguard Pathway Explained

From 1 October 2026 the Australian Government is resetting funding for two categories of NDIS support. This will affect all participants who receive funding for these supports. A separate safeguard pathway has been created for participants with the highest and most complex support needs, to ensure they continue to have enough funding to maintain 24-hour disability support safely. This article explains exactly who qualifies, how the pathway works and where a Functional Capacity Assessment strengthens an application.

How to Refer a Client for an NDIS FCA

How to Refer a Client for an NDIS FCA

If you or someone you support has been told they need a Functional Capacity Assessment, it is completely normal to feel unsure about what that actually means. This article explains what an NDIS Functional Capacity Assessment is

What is an NDIS Functional Capacity Assessment?

What is an NDIS Functional Capacity Assessment?

If you or someone you support has been told they need a Functional Capacity Assessment, it is completely normal to feel unsure about what that actually means. This article explains what an NDIS Functional Capacity Assessment is